BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
The week's Intelligence in one email, every Friday morning.
Regulatory moves, trial readouts, supply-chain news. No product pitches. Unsubscribe in one click.
Industry & Community
Same Day, Different Strategies: How Lilly's $6.5 Billion Houston Groundbreaking and Novo's Capital Markets Day Reveal Diverging Paths in the Oral GLP-1 Manufacturing Race
On 21 September 2026, Eli Lilly broke ground on a $6.5 billion API facility in Houston and Novo Nordisk hosted its Capital Markets Day in London, where it pledged to scale oral GLP-1 manufacturing tenfold by 2030. The two announcements — made on the same day — illuminate fundamentally different production strategies and have direct implications for the peptide supply chain.
26 Sep 2026
Industry & Community
The Oral Peptide Delivery Race: Approvals, Formulation Science, and the Investment Wave Reshaping Drug Development in 2026
A cluster of FDA approvals, landmark partnership deals, and oversubscribed financing rounds in 2026 signals that oral delivery of peptide therapeutics is transitioning from a persistent scientific aspiration to a commercially credible drug class. Research-procurement teams sourcing peptide APIs and formulation materials need to understand the technical and market forces now driving this shift.
21 Sep 2026
Industry & Community
Samsung Biologics' PolyPeptide Tender Window Opens Today: What the CHF 1.46 Billion Bid Means for Peptide API Supply
The formal acceptance period for Samsung Biologics' all-cash offer to acquire PolyPeptide Group opened on 15 September 2026, running until 12 October. With PolyPeptide's largest shareholder already committed to tender its 55.65% stake, completion appears probable — reshaping who controls a significant share of globally validated solid-phase peptide synthesis capacity.
15 Sep 2026
Industry & Community
Peptide CDMO Consolidation Accelerates: Samsung Biologics Launches Formal Tender for PolyPeptide as CordenPharma Closes AmbioPharm Deal
Samsung Biologics published its formal tender offer prospectus for Swiss peptide CDMO PolyPeptide Group on 31 August 2026, opening a ten-day cooling-off period ahead of the main acceptance window. The CHF 1.46 billion all-cash bid — carrying a 40 per cent premium to the pre-speculation share price — arrives weeks after CordenPharma completed its acquisition of AmbioPharm, signalling a sharp acceleration in consolidation among specialist peptide contract manufacturers.
02 Sep 2026
Industry & Community
Samsung Biologics' $1.8 Billion PolyPeptide Acquisition: What Peptide CDMO Consolidation Means for Research Supply Chains
Samsung Biologics has launched an all-cash tender offer to acquire Swiss peptide CDMO PolyPeptide Group for approximately $1.8 billion — the largest biopharma acquisition in South Korean history. With the formal offer prospectus due by 31 August 2026, procurement teams should understand what accelerating CDMO consolidation means for peptide API availability and supply-chain resilience.
11 Aug 2026
Industry & Community
Orforglipron and the Non-Peptide GLP-1: Why a Small-Molecule Approval Matters to the Peptide Research Sector
Eli Lilly's orforglipron (Foundayo) was FDA-approved in April 2026 as the first oral small-molecule GLP-1 receptor agonist — a compound that is structurally not a peptide. Its MHRA review is under way, with a potential UK marketing authorisation in late 2026. For research-procurement professionals, the distinction matters: orforglipron's approval reframes the competitive landscape for peptide-based GLP-1 manufacturing and signals where the next phase of obesity pharmacology is heading.
05 Aug 2026
Industry & Community
Samsung Biologics' $1.8 Billion PolyPeptide Bid: What the Deal Signals for Global Peptide Manufacturing Capacity
Samsung Biologics launched a CHF 1.46 billion all-cash tender offer for Swiss peptide CDMO PolyPeptide Group on 20 July 2026 — the largest-ever Korean biopharma acquisition. The move accelerates a consolidation wave in peptide contract manufacturing driven by sustained GLP-1 demand, and carries direct implications for research-procurement teams monitoring API supply-chain resilience.
31 Jul 2026
Industry & Community
Samsung Biologics Bids $1.8 Billion for Swiss Peptide CDMO PolyPeptide Group in Korea's Largest-Ever Pharma Deal
Samsung Biologics launched an all-cash public tender offer of CHF 1.46 billion ($1.8 billion) for Switzerland's PolyPeptide Group on 20 July 2026 — the largest biopharmaceutical M&A transaction in South Korean history. The deal brings a 70-year-old peptide CDMO, six GMP-certified manufacturing sites, and direct exposure to GLP-1 API demand under Samsung Biologics' roof, and signals how urgently global CDMO operators are moving to secure peptide manufacturing capacity ahead of a projected $29…
25 Jul 2026
Industry & Community
The Oral GLP-1 Race in 2026: What the Shift from Peptide Injections to Small-Molecule Pills Means for the Research Supply Chain
The MHRA approved the first oral GLP-1 tablet for weight loss in June 2026, and the FDA followed with orforglipron (Foundayo) — the first non-peptide small-molecule GLP-1 — in April. Head-to-head trial data now favour the small-molecule entrant on both glycaemic control and weight loss, raising structural questions for peptide API manufacturers and research-grade suppliers about where future demand will concentrate.
25 Jul 2026
Industry & Community
Macrocyclic Peptides: How a $1.8bn Novartis Deal and a String of Venture Rounds Signalled the Modality's Arrival in 2026
Macrocyclic peptides — ring-shaped molecules that sit between small molecules and biologics — have attracted more than $500 million in venture funding and several billion dollars in licensing deals in the first half of 2026. The capital surge reflects growing conviction that AI-assisted platform chemistry can now reliably produce oral macrocycles against targets that have resisted conventional drug design. Research procurement teams sourcing peptide compounds should understand what is driving…
10 Jul 2026
Industry & Community
The Oral GLP-1 Race in 2026: What the Wegovy Pill, Foundayo, and the NICE July Appraisal Mean for UK Research Procurement
The MHRA approved oral semaglutide (Wegovy pill) in June 2026 and a NICE committee is due to meet this month to assess orforglipron (Foundayo) for NHS use. With two mechanistically distinct oral GLP-1 agents now in or approaching the UK market, procurement teams need to understand the clinical differentiation, supply implications, and regulatory timelines that will shape research and clinical access.
07 Jul 2026
Industry & Community
The Oral Peptide Race: How 2026's Approvals and Investment Wave Are Reshaping Peptide Drug Development
Two landmark FDA approvals in early 2026 — Eli Lilly's orforglipron (Foundayo) and Johnson & Johnson's icotrokinra (ICOTYDE) — have validated oral peptide and peptide-mimetic delivery as a commercially viable drug class. Backed by hundreds of millions in fresh venture capital, the sector is moving rapidly from injectable-only paradigms toward once-daily pills. For UK research-procurement teams, the shift has direct implications for the tools, reference compounds, and analytical standards their…
23 Jun 2026